HiFiBiO Therapeutics
Cambridge
About HiFiBiO Therapeutics
HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $179.5M
- Funding stage: Late Stage Venture
- Last round: Series D (Jun 2021)
- Website: hifibio.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hifibio-therapeutics-83816 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.